TMCnet News
www.Xtremepicks.Com: Xtremepicks Alerts November 17, 2009 : CYCC, VIRL, ARMH and UMBF(M2 PressWIRE Via Acquire Media NewsEdge) Xtremepicks.com Alerts include Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq:CYCCP), Virage Logic Corporation (NASDAQ: VIRL), ARM (LSE:ARM) (Nasdaq: ARMH) and UMB Financial Corporation (NASDAQ: UMBF) Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) trading at $0.83 per share on trading volume of 15,817 shares. In a press release out on November 17, Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Society of Hematology Meeting BERKELEY HEIGHTS, N.J., Nov 17, 2009 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of advanced myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at two poster presentations during the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA, on Saturday, December 5, 2009. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a diversified biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib. Seliciclib, a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(R) Liquid and Numoisyn(R) Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information. Virage Logic Corporation (NASDAQ:VIRL) trading at $5.77 per share on trading volume of 1,773 shares. In a press release out on November 17, Virage Logic Completes Acquisition of NXP's Horizontal Advanced CMOS Semiconductor IP Technology and Development Team Multi-Year $60 Million Strategic Alliance Also Calls for Virage Logic to Serve as NXP's Trusted IP Partner FREMONT, Calif., Nov 17, 2009 -- Virage Logic Corporation (NASDAQ:VIRL), the semiconductor industry's trusted IP partner, today announced it has completed the acquisition of NXP's horizontal advanced CMOS intellectual property (IP) rights and certain engineering talent and equipment. As part of the acquisition, approximately 150 former NXP employees and the assets associated with selected NXP advanced CMOS libraries, IP blocks and SoC infrastructure along with other classes of semiconductor IP, including approximately 25 associated patent families, are now part of Virage Logic. The strategic alliance between the two companies also includes a multi-year, $60 million licensing and IP development relationship that further executes on NXP's strategic vision to achieve leadership in high performance mixed signal and enables them to significantly reduce costs without compromising design capability. About Virage Logic Virage Logic is a leading provider of both functional and physical semiconductor intellectual property (IP) for the design of complex integrated circuits. The company's highly differentiated product portfolio includes processor solutions, interface IP solutions, embedded SRAMs and NVMs, embedded memory test and repair, logic libraries, and memory development software. As the industry's trusted semiconductor IP partner, more than 400 foundry, IDM and fabless customers rely on Virage Logic to achieve higher performance, lower power, higher density and optimal yield, as well as shorten time-to-market and time-to-volume. For further information, visit http://www.viragelogic.com. ARM (LSE:ARM) (Nasdaq:ARMH) trading at $7.98 on a volume of 222,885 shares In a press release out on November 17, ARM Launches Solution Center to Foster Innovation and Speed Development of Android-Powered Devices Tools, Solutions and Services From ARM Connected Community to Fuel Next-Generation of Open Source Mobile and Connected Devices CAMBRIDGE, England, Nov 17, 2009 -- As part of its continued work to foster innovation and openness in connected devices, ARM (LSE:ARM) (Nasdaq:ARMH) today announced the Solution Center for Android(TM), a resource for designers and developers of ARM(R) technology-based products running on Android, the open source platform from the Open Handset Alliance(TM). More than 35 members of the ARM Connected Community(TM) have joined this initiative, once again demonstrating the strength of the ARM ecosystem. About ARM ARM designs the technology that lies at the heart of advanced digital products, from wireless, networking and consumer entertainment solutions to imaging, automotive, security and storage devices. ARM's comprehensive product offering includes 32-bit RISC microprocessors, graphics processors, video engines, enabling software, cell libraries, embedded memories, high-speed connectivity products, peripherals and development tools. Combined with comprehensive design services, training, support and maintenance, and the company's broad Partner community, they provide a total system solution that offers a fast, reliable path to market for leading electronics companies. More information on ARM is available at http://www.arm.com. UMB Financial Corporation (NASDAQ: UMBF) trading at $39.90 on a volume of 22,059 shares In a press release out on November 17, UMB Healthcare Services Launches Claims Reimbursement Portal KANSAS CITY, Mo., Nov 17, 2009 -- UMB Healthcare Services, a division of UMB Financial Corporation (NASDAQ: UMBF), announced today it is offering clients a unique, integrated claims reimbursement portal, Healthcare Exchange(TM). About UMB: UMB Financial Corporation (NASDAQ: UMBF) is a financial services holding company headquartered in Kansas City, Mo., offering complete banking, asset management, health spending solutions and related financial services to both individual and business customers nationwide. Its banking subsidiaries own and operate 135 banking centers throughout Missouri, Illinois, Colorado, Kansas, Oklahoma, Nebraska and Arizona. Subsidiaries of the holding company and the lead bank, UMB Bank, n.a., include mutual fund and alternative investment services groups, single-purpose companies that deal with brokerage services and insurance, and a registered investment advisor that manages the company's proprietary mutual funds and investment advisory accounts for institutional customers. Visit umb.com for more company information. Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience. Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at [email protected] Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |